Aurora Cannabis - CEO, Miguel Martin.
CEO, Miguel Martin.
Source: Aurora Cannabis.
  • Aurora Cannabis (ACB) has repurchased C$31.3 million of the principal of its convertible senior notes
  • Total consideration, including accrued interest, was $29.8 million in cash, which amounts to a 5.45-per-cent discount on par value
  • The transaction will reduce annual interest payments by $11.9 million
  • The company expects a positive adjusted EBITDA run rate by year-end
  • Aurora is a global cannabis company headquartered in Edmonton, Alberta, serving the medical and retail markets
  • Aurora Cannabis (ACB) is down by 8.29 per cent, trading at $1.66 per share

Aurora Cannabis (ACB) has repurchased C$31.3 million of the principal of its convertible senior notes.

Total consideration, including accrued interest, was $29.8 million in cash, which amounts to a 5.45-per-cent discount to par value.

The company executed the transaction to reduce debt and annual cash interest costs. Annual cash interest savings from the repurchases from Q3 2022 onward total approximately $11.9 million.

Aurora’s balance sheet remains strong, with $380 million in cash and cash equivalents, including $52 million of restricted cash.

It expects to achieve a positive adjusted EBITDA run rate by December 31, 2022.

Aurora is a global cannabis company headquartered in Edmonton, Alberta, serving the medical and retail markets.

Aurora Cannabis (ACB) is down by 8.29 per cent, trading at $1.66 per share at 9:46 am EST.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.